NEW YORK (GenomeWeb News) - Affymetrix recently decided to hand over ownership of its Clinical Laboratory Improvement Amendments-compliant lab to direct-to-customer genetic-testing firm Navigenics as part of a strategy to refocus on being a platform provider.

The move comes as an increasing number of drug makers outsource their molecular diagnostic research needs to CLIA labs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.